Biopsy, immunostains, imaging, and what the stage means for your plan
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Merkel cell carcinoma (MCC) is notorious for looking harmless. It often resembles a cyst, a stye, an insect bite, or an ordinary pink bump, which is why the diagnosis is frequently a surprise. Because MCC can move quickly, a clear diagnostic and staging work-up in the first few weeks sets the direction for everything that follows.
This guide walks through how the diagnosis is confirmed under the microscope, why imaging and lymph node testing are almost always part of the picture, and how all of that information comes together into a stage that shapes your treatment plan.
The diagnosis starts with a biopsy — removing all or part of the lump so a pathologist can examine it. Under the microscope, MCC shows small, round, blue-staining cells with features of a neuroendocrine tumor. Because these cells can resemble other small-round-cell cancers, appearance alone is not enough to be certain.
Pathologists apply special stains that tag particular proteins. MCC characteristically stains positive for cytokeratin 20 (CK20) in a dot-like pattern and for neuroendocrine markers, while staining negative for TTF-1, a marker of small-cell lung cancer. This panel is what distinguishes MCC from a skin metastasis of a lung tumor or from lymphoma. Many centers also test the tumor for the Merkel cell polyomavirus.
Once MCC is confirmed, the report describes the tumor's size, how deeply it extends, whether it reaches the edges of the removed tissue (margins), and whether cancer is seen inside small blood or lymphatic vessels (lymphovascular invasion). These details feed directly into staging and surgical planning.
MCC spreads to regional lymph nodes early, and often before those nodes are large enough to feel. Two tools address this:
Most people with newly diagnosed MCC have baseline imaging — commonly a whole-body PET/CT, or CT of the chest, abdomen, and pelvis, sometimes with brain MRI. Imaging looks for disease in lymph nodes and distant organs that the exam cannot reach, and it creates a baseline that later scans are compared against. Imaging findings can raise the stage, but a biopsy is still needed to confirm anything suspicious before it is called metastatic disease.
MCC uses the American Joint Committee on Cancer (AJCC) staging system, which combines the primary tumor (T), lymph nodes (N), and distant spread (M). In plain terms:
Staging also distinguishes clinical stage (based on exam and imaging) from pathologic stage (which adds what surgery and lymph node biopsy reveal). Pathologic staging is more accurate, which is one reason SLNB matters so much in MCC.
Diagnosing and staging MCC takes a coordinated sequence: a biopsy with immunostains to confirm what it is, lymph node evaluation (usually including a sentinel node biopsy) to see whether it has started to travel, and imaging to check for disease farther away. The resulting stage is the single best predictor of what to expect and the foundation of the treatment plan.
Because MCC is rare, ask whether your care can be coordinated by a team that treats it regularly — experience genuinely matters here.
Disclaimer: Educational only. Not a substitute for professional medical advice. Always consult your dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for personalized information about Merkel cell carcinoma
Chat with the Navigator